FDA Hosts Webinar for Stage 1 Requirements under LDT Final Rule
FDA Law Blog: Biosimilars
SEPTEMBER 22, 2024
The webinar largely consisted of summarizing the general requirements under Parts 803, 806 and 820.198, which we do not reproduce here ( but see another of our prior blog posts discussing these requirements and their applicable to LDTs in greater detail; you can also find FDA’s slides from the webinar here ). By Steven J.
Let's personalize your content